BioCentury | May 9, 2020
Product Development

With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond

Amgen’s 2019 takeout of DNA-encoded library (DEL) company Nuevolution is fueling the big biotech’s move into the crowded field of targeted protein degradation. The team that drove the acquisition will also use DELs to discover...
BioCentury | May 4, 2020
Product Development

Investors see little value in remaining Newron programs following Rett syndrome failure

The failure of Newron’s sarizotan in Rett syndrome leaves the company with two pipeline programs, but its valuation is now trading near its cash position -- a sign that investors see little value in what...
BioCentury | Mar 4, 2020
Product Development

Hidden consequences of COVID-19: Why small biotechs can’t just wait this one out

It’s still anyone’s guess as to how long the COVID-19 outbreak will take to peak, let alone wane after that. But small biotechs could see knock-on effects that play out over a longer time frame...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BioCentury | Nov 7, 2019
Product Development

AZ replants R&D roots in China, goes all-in on innovation

In a big week for MNCs in China, AstraZeneca defined the latest move in its China strategy with an ‘all-in’ approach to innovation that goes full throttle by fostering R&D, AI and company formation. As...
BC Innovations | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

Interest in kidney diseases is mounting among investors, biotechs and pharmas at a rate reminiscent of the liver disease explosion almost a decade ago. The momentum is driven by improvements at both ends of the...
BioCentury | Sep 21, 2019
Politics, Policy & Law

Congress won’t adopt Pelosi’s price controls, but it may revamp Medicare Part D

The fate of drug pricing legislation, and the fortunes of American patients and biopharmaceutical companies, hinge on calculations five politicians will make over the coming 100 days. If leadership in the House and Senate and...
BioCentury | Aug 31, 2019
Product Development

Privacy, transparency and consent

Patients need to control the use of their data. This calls for new policies on transparency and consent, and means establishing systems governing the ownership, collection and agency of those data. Data privacy is probably...
BC Innovations | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BioCentury | Aug 16, 2019
Product Development

ACRES’ plan to harmonize clinical trials across many lands

With the launch of its clinical site accreditation program, ACRES has taken the first step toward its larger goal of creating a clinical research infrastructure that is digitally connected and operates under a single set...
Items per page:
1 - 10 of 34